Additional file 2 of Circular RNA circATP9A promotes non-small cell lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization
Introduction C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1% to 2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor
Technological advancements in the Non-Small Cell Lung Cancer industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transform
Purpose This systematic review with network meta-analysis compared the efficacy and safety of currently licensed second-line treatments in patients with late stage non-small cell lung cancer (NSCLC).
